YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Phase II Flub for Peregrine

September 24, 2012 | A week after releasing favorable Phase II results for the novel vascular-targeting immunotherapy for non-small cell lung cancer, bavituximab, study sponsor Peregrine Pharmaceuticals has announced "major discrepancies" in the trial. Peregrine blames the research oversight team in charge of the trial (they were blinded), but the announcement still resulted in plummeting Peregrine stock. Cancer Grace
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.